Jasper Therapeutics, Inc. (JSPR)

Market Cap	323.58M
Revenue (ttm)	n/a
Net Income (ttm)	-63.53M
Shares Out	15.00M
EPS (ttm)	-4.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,814
Open	21.12
Previous Close	21.53
Day's Range	21.00 - 22.11
52-Week Range	5.00 - 31.01
Beta	2.19
Analysts	Strong Buy
Price Target	73.38 (+240.2%)
Earnings Date	Nov 7, 2024

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lowe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR
• Website: https://www.jaspertherapeutics.com/

Analyst Forecast

According to 11 analysts, the average rating for JSPR stock is "Strong Buy." The 12-month stock price forecast is $73.38, which is an increase of 240.20% from the latest price.

Price Target

$73.38

(240.20% upside)

Analyst Consensus: Strong Buy